NeuBase Therapeutics Past Earnings Performance
Past criteria checks 0/6
NeuBase Therapeutics has been growing earnings at an average annual rate of 26.6%, while the Biotechs industry saw earnings growing at 14.7% annually.
Key information
26.6%
Earnings growth rate
28.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -170.2% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
No updates
Recent updates
Can NeuBase Therapeutics (NASDAQ:NBSE) Afford To Invest In Growth?
Aug 26
NeuBase Therapeutics GAAP EPS of -$0.26 beats by $0.04
Aug 11NeuBase Therapeutics promotes Dr. William Mann to President and COO
Jun 29We Think NeuBase Therapeutics (NASDAQ:NBSE) Needs To Drive Business Growth Carefully
May 12Is NeuBase Therapeutics (NASDAQ:NBSE) In A Good Position To Deliver On Growth Plans?
Jan 24Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation
Oct 02Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation
Jun 02Have Insiders Been Buying NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Shares This Year?
Feb 23We Think NeuBase Therapeutics (NASDAQ:NBSE) Can Afford To Drive Business Growth
Jan 19NeuBase Therapeutics EPS in-line
Dec 23NeuBase Therapeutics reports encouraging data for PATrOL-enabled anti-gene in a type of muscular dystrophy
Dec 16Do Insiders Own Lots Of Shares In NeuBase Therapeutics, Inc. (NASDAQ:NBSE)?
Dec 15Revenue & Expenses Breakdown
How NeuBase Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 23 | 0 | -25 | 11 | 13 |
| 31 Dec 22 | 0 | -30 | 12 | 18 |
| 30 Sep 22 | 0 | -34 | 12 | 21 |
| 30 Jun 22 | 0 | -33 | 13 | 20 |
| 31 Mar 22 | 0 | -33 | 13 | 20 |
| 31 Dec 21 | 0 | -29 | 12 | 17 |
| 30 Sep 21 | 0 | -25 | 12 | 14 |
| 30 Jun 21 | 0 | -23 | 11 | 13 |
| 31 Mar 21 | 0 | -18 | 10 | 9 |
| 31 Dec 20 | 0 | -17 | 10 | 8 |
| 30 Sep 20 | 0 | -17 | 10 | 7 |
| 30 Jun 20 | 0 | -33 | 13 | 19 |
| 31 Mar 20 | 0 | -31 | 12 | 18 |
| 31 Dec 19 | 0 | -29 | 11 | 17 |
| 30 Sep 19 | 0 | -26 | 9 | 16 |
Quality Earnings: NBSE is currently unprofitable.
Growing Profit Margin: NBSE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if NBSE's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare NBSE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NBSE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: NBSE has a negative Return on Equity (-170.17%), as it is currently unprofitable.